February 23, 2016 – Instradent USA, Inc. filed a petition for inter partes review of multiple claims of Nobel Biocare Services AG’s patent. Instradent contended that the claims are unpatentable under 35 U.S.C. §§ 102 and 103 over prior art publications. The USPTO issued a decision on February 19, 2016 finding that the information presented in Instradent’s petition establishes a reasonable likelihood that Instradent will prevail in showing that several claims of Nobel Biocare’s patent are unpatentable. The USPTO has instituted an inter partes review on some of the challenged claims. The patent at issue is U.S. Patent No. 8,714,977, entitled “Condensing skeletal implant that facilitate insertions” and the claims the USPTO will review are claims 1-5, 19, and 20.
The petition is pending in the United States Patent Trial and Appeal Board and is captioned: Petition for Inter Partes Review by Instradent USA, Inc., PTAB-IPR2015-01786.
By: Rachael Million-Perez